Advertisement

The AAPS Journal

, Volume 11, Issue 2, pp 364–370 | Cite as

Structure-Based Prediction of the Nonspecific Binding of Drugs to Hepatic Microsomes

Research Article

Abstract

For the accurate prediction of in vivo hepatic clearance or drug–drug interaction potential through in vitro microsomal metabolic data, it is essential to evaluate the fraction unbound in hepatic microsomal incubation media. Here, a structure-based in silico predictive model of the nonspecific binding (fumic, fraction unbound in hepatic microsomes) for 86 drugs was successfully developed based on seven selected molecular descriptors. The R 2 of the predicted and observed log((1 − fumic)/fumic) for the training set (n = 64) and test set (n = 22) were 0.82 and 0.85, respectively. The average fold error (AFE, calculated by fumic rather than log((1 − fumic)/fumic)) of the in silico model was 1.33 (n = 86). The predictive capability of fumic for neutral drugs compared well to that for basic compounds (R 2 = 0.82, AFE = 1.18 and fold error values were all below 2, except for felodipine and progesterone) in our model. This model appears to perform better for neutral compounds when compared to models previously published in the literature. Therefore, this in silico model may be used as an additional tool to estimate fumic and for predicting in vivo hepatic clearance and inhibition potential from in vitro hepatic microsomal studies.

Key words

fraction unbound in hepatic microsomes in silico prediction molecular descriptors 

Notes

Acknowledgements

We are thankful to Accelrys Inc. for providing 1-month free evaluation of TSAR software in 2007.

References

  1. 1.
    Ito K, Houston JB. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 2005;22:103–12.PubMedCrossRefGoogle Scholar
  2. 2.
    Rostami-Hodjegan A, Tucker GT. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 2007;6:140–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Miners JO, Smith PA, Sorich MJ, McKinnon RA, Mackenzie PI. Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu Rev Pharmacol Toxicol 2004;44:1–25.PubMedCrossRefGoogle Scholar
  4. 4.
    Ito K, Brown HS, Houston JB. Database analyses for the prediction of in vivo drug–drug interactions from in vitro data. Br J Clin Pharmacol 2004;57:473–86.PubMedCrossRefGoogle Scholar
  5. 5.
    Polasek TM, Miners JO. Quantitative prediction of macrolide drug–drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate. Eur J Clin Pharmacol 2006;62:203–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Uchaipichat V, Winner LK, Mackenzie PI, Elliot DJ, Williams JA, Miners JO. Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol 2006;61:427–39.PubMedCrossRefGoogle Scholar
  7. 7.
    Grime K, Riley RJ. The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug–drug interactions. Curr Drug Metab 2006;7:251–64.PubMedCrossRefGoogle Scholar
  8. 8.
    Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 1999;27:1350–9.PubMedGoogle Scholar
  9. 9.
    Riley RJ, McGinnity DF, Austin RP. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 2005;33:1304–11.PubMedCrossRefGoogle Scholar
  10. 10.
    Margolis JM, Obach RS. Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions. Drug Metab Dispos 2003;31:606–11.PubMedCrossRefGoogle Scholar
  11. 11.
    Brown HS, Galetin A, Hallifax D, Houston JB. Prediction of in vivo drug–drug interactions from in vitro data : factors affecting prototypic drug–drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin Pharmacokinet 2006;45:1035–50.PubMedCrossRefGoogle Scholar
  12. 12.
    Tran TH, Von Moltke LL, Venkatakrishnan K, Granda BW, Gibbs MA, Obach RS, Harmatz JS, Greenblatt DJ. Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. Drug Metab Dispos 2002;30:1441–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Jones HM, Houston JB. Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations. Drug Metab Dispos 2004;32:973–82.PubMedCrossRefGoogle Scholar
  14. 14.
    Soars MG, Burchell B, Riley RJ. in vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther 2002;301:382–90.PubMedCrossRefGoogle Scholar
  15. 15.
    Ghanbari F, Rowland-Yeo K, Bloomer JC, Clarke SE, Lennard MS, Tucker GT, Rostami-Hodjegan A. A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation. Curr Drug Metab 2006;7:315–34.PubMedCrossRefGoogle Scholar
  16. 16.
    Austin RP, Barton P, Cockroft SL, Wenlock MC, Riley RJ. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos 2002;30:1497–503.PubMedCrossRefGoogle Scholar
  17. 17.
    Hallifax D, Houston JB. Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement. Drug Metab Dispos 2006;34:724–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Gertz M, Kilford PJ, Houston JB, Galetin A. Drug lipophilicity and microsomal protein concentration as determinants in the prediction of the fraction unbound in microsomal incubations. Drug Metab Dispos 2008;36:535–42.PubMedCrossRefGoogle Scholar
  19. 19.
    Sykes MJ, Sorich MJ, Miners JO. Molecular modeling approaches for the prediction of the nonspecific binding of drugs to hepatic microsomes. J Chem Inf Model 2006;46:2661–73.PubMedCrossRefGoogle Scholar
  20. 20.
    Gao H, Yao L, Mathieu HW, Zhang Y, Maurer TS, Troutman MD, Scott DO, Ruggeri RB, Lin J. In silico modeling of non-specific binding to human liver microsomes. Drug Metab Dispos 2008;36(10):2130–5.PubMedCrossRefGoogle Scholar
  21. 21.
    TSAR. 3.3 Reference Guide, Oxford Molecular Limited, 2000.Google Scholar
  22. 22.
  23. 23.
    O’Reilly SA, Wilson AM, Howes B. Utilization of SciFinder Scholar at an Undergraduate Institution. J Chem Educ 2002;79:524–6.CrossRefGoogle Scholar
  24. 24.
    Li J, Sun J, Cui S, He Z. Quantitative structure-retention relationship studies using immobilized artificial membrane chromatography I: amended linear solvation energy relationships with the introduction of a molecular electronic factor. J Chromatogr A 2006;1132:174–82.PubMedCrossRefGoogle Scholar
  25. 25.
    Houston JB, Carlile DJ. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab Rev 1997;29:891–922.PubMedCrossRefGoogle Scholar
  26. 26.
    Honig B, Sharp K, Yang A. Macroscopic models of aqueous solutions: biological and chemical application. J Phys Chem 1993;97:1101–9.CrossRefGoogle Scholar
  27. 27.
    Krämer SD, Braun A, Jakits-Deiser C, Wunderli-Allenspach H. Towards the predictability of drug-lipid membrane interactions: the pH-dependent affinity of propanolol to phosphatidylinositol containing liposomes. Pharm Res 1998;15:739–44.PubMedCrossRefGoogle Scholar
  28. 28.
    Kilford PJ, Gertz M, Houston JB, Galetin A. Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data. Drug Metab Dispos 2008;36:1194–7.PubMedCrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2009

Authors and Affiliations

  • Haiyan Li
    • 1
  • Jin Sun
    • 1
  • Xiaofan Sui
    • 1
  • Zhongtian Yan
    • 1
  • Yinghua Sun
    • 1
  • Xiaohong Liu
    • 1
  • Yongjun Wang
    • 1
  • Zhonggui He
    • 1
  1. 1.Department of Biopharmaceutics, School of PharmacyShenyang Pharmaceutical UniversityShenyangChina

Personalised recommendations